892 F.3d 1194
Fed. Cir.2018Background
- Xitronix sued KLA‑Tencor alleging a Walker Process antitrust claim: KLA obtained and enforced a patent by fraud/inequitable conduct in PTO prosecution, rendering the patent unenforceable.
- The district court (W.D. Tex.) reviewed patent prosecution records and held Xitronix failed to prove fraud/inequitable conduct.
- Xitronix appealed to the Federal Circuit. The three‑judge panel sua sponte questioned Federal Circuit jurisdiction under 28 U.S.C. §1295(a)(1).
- The panel concluded the patent issues were not a "substantial question of patent law" post‑Gunn v. Minton and transferred the appeal to the Fifth Circuit.
- KLA‑Tencor sought panel and en banc rehearing; the Federal Circuit denied rehearing en banc. Judge Newman dissented from the denial, arguing the panel decision contradicts statute and controlling precedent and that the Federal Circuit must retain exclusive appellate jurisdiction over Walker Process appeals.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether the Federal Circuit has exclusive appellate jurisdiction over this Walker Process appeal | Xitronix: appeal "arises under" patent law because resolution of fraud/inequitable conduct in PTO is necessary to antitrust claim and will render the patent unenforceable | KLA: (implicit) patent issues not sufficiently "substantial" under Gunn to invoke §1295(a)(1); transfer appropriate | Panel: Federal Circuit lacks jurisdiction because the patent issue here is not a "substantial" question of patent law post‑Gunn; appeal transferred to Fifth Circuit; en banc rehearing denied (Newman dissented) |
| Whether Gunn v. Minton removed Federal Circuit jurisdiction over Walker Process claims | Xitronix: Gunn is distinguishable (was a backward‑looking malpractice case) and did not strip Fed. Cir. jurisdiction over claims that actually affect patent validity/enforceability | Panel: invoked Gunn to conclude the patent question here is not substantial to the federal system | Panel: applied Gunn to justify transfer; Newman: Gunn does not support this result |
| Whether alleged fraud/inequitable conduct in PTO is a "substantial question of patent law" | Xitronix: fraud in procurement directly affects patent validity/enforceability—a core Federal Circuit subject | KLA: the panel treated the issue as not meeting the Gunn substantiality guideposts | Panel: concluded issue insufficiently "substantial"; Newman: such issues are traditionally and properly within Federal Circuit jurisdiction |
| Whether the panel decision conflicts with Federal Circuit precedent (Nobelpharma, Ciprofloxacin, etc.) | Xitronix: longstanding Fed. Cir. precedent places prosecution fraud/Walker Process issues within Federal Circuit appellate jurisdiction | KLA/panel: relied on Gunn and several regional circuit decisions to support transfer | Panel: transferred despite tensions with prior Fed. Cir. precedent; Newman: transfer contradicts en banc precedent and warrants en banc review |
Key Cases Cited
- Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., 382 U.S. 172 (1965) (establishes Walker Process doctrine: patents procured by knowing fraud can support antitrust liability)
- Christianson v. Colt Indus. Operating Corp., 486 U.S. 800 (1988) (defines when a case "arises under" patent law for Federal Circuit jurisdiction)
- Gunn v. Minton, 568 U.S. 251 (2013) (sets four‑part test for substantial federal issue in state‑law claims and emphasizes federal‑state balance)
- Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996) (Congress created the Federal Circuit to promote uniformity in patent law)
- Nobelpharma AB v. Implant Innovations, Inc., 141 F.3d 1059 (Fed. Cir. 1998) (en banc) (holds fraudulent procurement/enforcement issues under Walker Process are within Federal Circuit jurisdiction)
- In re Ciprofloxacin Hydrochloride Antitrust Litig., 544 F.3d 1323 (Fed. Cir. 2008) (transferred appeal recognizing fraud before PTO as a substantial patent question)
- Madstad Eng’g, Inc. v. USPTO, 756 F.3d 1366 (Fed. Cir. 2014) (applies Gunn guideposts to preserve Federal Circuit's role in patent‑centric questions)
- Jang v. Boston Scientific Corp., 767 F.3d 1334 (Fed. Cir. 2014) (holds patent validity issues in contract disputes can be "substantial" and properly in Federal Circuit)
- Vermont v. MPHJ Tech. Inv’ts, LLC, 803 F.3d 635 (Fed. Cir. 2015) (distinguishes Gunn and finds substantial patent question in state‑law challenge affecting patents)
- In re Lipitor (Antitrust) Litig., 855 F.3d 126 (3d Cir. 2017) (Third Circuit retained jurisdiction over certain antitrust claims involving patents when non‑patent theories existed)
- MDS (Canada) Inc. v. Rad Source Techs., Inc., 720 F.3d 833 (11th Cir. 2013) (contract dispute where patent issues were not "substantial" because patents had expired)
- Seed Co. Ltd. v. Westerman, 832 F.3d 325 (D.C. Cir. 2016) (malpractice claim about unsuccessful prosecution was "backward‑looking" and did not raise substantial forward‑looking patent questions)